TKIs for Advanced HCC in the Second Line and Beyond

In this podcast episode from Clinical Care Options (CCO), Josep M. Llovet, MD, PhD, and Markus Peck-Radosavljevic, MD, MBA, discuss second line treatment of patients with advanced hepatocellular carcinoma. Topics include:

• Available agents for the management of advanced hepatocellular carcinoma in the second line
• The current role of tyrosine kinase inhibitors in second-line treatment of advanced hepatocellular carcinoma
• Ongoing clinical trials in the second-line setting

Presenters:  

Josep M. Llovet, MD, PhD, FAASLD
Professor of Medicine
Director, Mount Sinai Liver Cancer Program
Division of Liver Diseases
Mount Sinai School of Medicine
New York, New York
Professor of Research
Liver Unit, IDIBAPS
Hospital Clinic Barcelona
Barcelona, Spain

Univ. Prof. Markus Peck-Radosavljevic, MD, MBA
Professor of Medicine
Medical University of Vienna
Vienna, Austria
Department Chair, Innere Medizin und Gastroenterologie
Klinikum Klagenfurt am Wörthersee
Klagenfurt am Wörthersee, Austria

Link to full program, including accompanying downloadable slidesets:
https://bit.ly/2ZL9bxq